Lung Cancer (Diagnosis)IMMUNOPUMON2NCT07384897
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
A study testing Peripheral Blood Collection for Immune Profiling in people with Lung Cancer (Diagnosis) and Sarcoidosis, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth… Read more about this study
- Who is it for?
- Ages Up to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease
- What is being tested?
- Peripheral Blood Collection for Immune Profiling
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 425 participants
- Where
- 1 siteBelgium
- Study dates
- 17 Feb 2025to 17 Feb 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 80 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Diagnosis of lung cancer
- Presence of precancerous lung lesions
- Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment
- Control group: individuals without known lung disease
- Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
- Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected
Who cannot join
- Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
- Acute infection at the time of inclusion
- Refusal or inability to provide informed consent (or assent, when applicable)
- Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Cliniques universitaires saint Luc
Brussels, 1200
Frank Aboubakar Nana, MD; PhD, 0032 2 764 85 19, frank.aboubaka@saintluc.uclouvain.be
Kim Henquin, Study nurse, 0032 2 764 42 26, kim.henquin@saintluc.uclouvain.be
About this study
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Read more
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
- Conditions
- Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease, Immunotherapy Resistance, Immune Dysregulation
- Being tested
- Peripheral Blood Collection for Immune Profiling
- Keywords
- lung cancer, Non-Small Cell Lung Cancer, Sarcoidosis, Chronic Obstructive Pulmonary Disease, COPD, Immune Cells, Tumor Microenvironment, Immune Dysregulation, Immunotherapy, Immunotherapy Resistance, Immune Profiling, Myeloid Cells, Neutrophils, Dendritic Cells, Inflammation, Chronic Inflammation, Immune suppression, Emergency myelopoiesis
- Medical subject headings
- Lung Neoplasms, Disease, Sarcoidosis, Pulmonary Disease, Chronic Obstructive, Carcinoma, Non-Small-Cell Lung, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peripheral Blood Collection for Immune ProfilingOther
Participants provide biological samples for immune profiling and translational research. Samples include peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue or rlymph node, bone marrow. No experimental treatments are given. Collected samples are analyzed to characterize immune cell populations and their functional and molecular features, with the aim of studying immune mechanisms involved in lung cancer, sarcoidosis, and COPD, as well as factors associated with disease progression and treatment response. All medical care and treatment decisions remain independent of study participation.
| Study group | Role | What they receive |
|---|---|---|
| Patients with precancerous lung lesions | Other | Patients with precancerous lung lesions under clinical monitoring Receives: Other: Peripheral Blood Collection for Immune Profiling |
| Lung cancer | Active comparator | Patients with a diagnosis of lung cancer (all stages) Receives: Other: Peripheral Blood Collection for Immune Profiling |
| Sarcoidosis and COPD | Other | Patients with chronic inflammatory lung diseases Receives: Other: Peripheral Blood Collection for Immune Profiling |
| Control group | Other | Control group of volunteers without known lung disease Receives: Other: Peripheral Blood Collection for Immune Profiling |
| chronic granulomatous disease | Other | Children and adolescents weighing ≥10 kg with chronic granulomatous disease Receives: Other: Peripheral Blood Collection for Immune Profiling |
| Adults undergoing orthopedic surgery following hip or femur fracture | Other | Bone Marrow of Adults undergoing orthopedic surgery following hip or femur fracture Receives: Other: Peripheral Blood Collection for Immune Profiling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression free survival
median Progression free survival
Measured: Throughout the entire study, approximately during 7 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start17 Feb 2025
- Primary completion1 Dec 2030 (estimated)
- Study completion17 Feb 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Lung Cancer (Diagnosis)Studies of the same condition, open and under way.
- More trials run by Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This is a translational, non-interventional study evaluating immune cell populations in patients with lung cancer, sarcoidosis, and COPD. Participants receive only standard clinical care; no experimental treatments are given. Biological samples (primarily blood and when available, tumor, bone morrow samples collected for clinical reasons) and associated clinical data are analyzed to investigate immune mechanisms related to tumor progression, chronic lung inflammation, and response or resistance to therapy. The study is exploratory and comparative across diseases. All treatment decisions are made independently by the treating physicians and are not influenced by study participation.
- Masking
- None (open label)
- Enrolment
- 425 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Frank Aboubakar Nana, MD; PhD, Study director, Cliniques universistaires saint Luc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07384897
- Sponsor's protocol ID
- IMMUNOPOUMON2
- Acronym
- IMMUNOPUMON2
- Status last verified
- Jan 2026
- First submitted
- 26 Jan 2026
- Last updated
- 3 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Desai A, Prasad V. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 Oct;36(10):3202-3204. doi: 10.1007/s11606-021-06806-5. Epub 2021 Apr 26. No abstract available.
PubMed 33904047Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
PubMed 31050774Delhez N, Aboubakar Nana F, Houbion C, Bayard A, Bruger A, Vanhaver C, Brandau S, van der Bruggen P, Hirsch T. Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation. Methods Cell Biol. 2025;191:151-196. doi: 10.1016/bs.mcb.2024.10.010. Epub 2024 Nov 25.
PubMed 39824555Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21.
PubMed 29785656Vanhaver C, Aboubakar Nana F, Delhez N, Luyckx M, Hirsch T, Bayard A, Houbion C, Dauguet N, Brochier A, van der Bruggen P, Bruger AM. Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. Life Sci Alliance. 2023 Nov 6;7(1):e202302332. doi: 10.26508/lsa.202302332. Print 2024 Jan.
PubMed 37931958
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
- ClinicalTrials.gov ID
- NCT07384897
- Acronym / sponsor ID
- IMMUNOPUMON2 / IMMUNOPOUMON2
- Conditions
- Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease, Immunotherapy Resistance, Immune Dysregulation
- Keywords
- lung cancer, Non-Small Cell Lung Cancer, Sarcoidosis, Chronic Obstructive Pulmonary Disease, COPD, Immune Cells, Tumor Microenvironment, Immune Dysregulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 425 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 17 Feb 2025 (actual)
- Primary completion
- 1 Dec 2030 (estimated)
- Study completion
- 17 Feb 2032 (estimated)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- This is a translational, non-interventional study evaluating immune cell populations in patients with lung cancer, sarcoidosis, and COPD. Participants receive only standard clinical care; no experimental treatments are given. Biological samples (primarily blood and when available, tumor, bone morrow samples collected for clinical reasons) and associated clinical data are analyzed to investigate immune mechanisms related to tumor progression, chronic lung inflammation, and response or resistance to therapy. The study is exploratory and comparative across diseases. All treatment decisions are made independently by the treating physicians and are not influenced by study participation.
| Arm | Type | Receives |
|---|---|---|
| Patients with precancerous lung lesions | Other | Other: Peripheral Blood Collection for Immune ProfilingPatients with precancerous lung lesions under clinical monitoring |
| Lung cancer | Active comparator | Other: Peripheral Blood Collection for Immune ProfilingPatients with a diagnosis of lung cancer (all stages) |
| Sarcoidosis and COPD | Other | Other: Peripheral Blood Collection for Immune ProfilingPatients with chronic inflammatory lung diseases |
| Control group | Other | Other: Peripheral Blood Collection for Immune ProfilingControl group of volunteers without known lung disease |
| chronic granulomatous disease | Other | Other: Peripheral Blood Collection for Immune ProfilingChildren and adolescents weighing ≥10 kg with chronic granulomatous disease |
| Adults undergoing orthopedic surgery following hip or femur fracture | Other | Other: Peripheral Blood Collection for Immune ProfilingBone Marrow of Adults undergoing orthopedic surgery following hip or femur fracture |
Who may qualify
- Ages
- Up to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Diagnosis of lung cancer
- Presence of precancerous lung lesions
- Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment
- Control group: individuals without known lung disease
- Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
Key exclusion criteria (4 listed)
- Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
- Acute infection at the time of inclusion
- Refusal or inability to provide informed consent (or assent, when applicable)
- Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peripheral Blood Collection for Immune ProfilingParticipants provide biological samples for immune profiling and translational research. Samples include peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue or rlymph node, bone marrow. No experimental treatments are given. Collected samples are analyzed to characterize immune cell populations and their functional and molecular features, with the aim of studying immune mechanisms involved in lung cancer, sarcoidosis, and COPD, as well as factors associated with disease progression and treatment response. All medical care and treatment decisions remain independent of study participation. | Other | Adults undergoing orthopedic surgery following hip or femur fracture, Control group, Lung cancer, Patients with precancerous lung lesions, Sarcoidosis and COPD, chronic granulomatous disease |
Primary outcome
Progression free survival
Time frame: Throughout the entire study, approximately during 7 years
median Progression free survival
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2026.
- Results publication: PubMed 33904047Desai A, Prasad V. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 Oct;36(10):3202-3204. doi: 10.1007/s11606-021-06806-5. Epub 2021 Apr 26. No abstract available.
- Results publication: PubMed 31050774Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
- Results publication: PubMed 39824555Delhez N, Aboubakar Nana F, Houbion C, Bayard A, Bruger A, Vanhaver C, Brandau S, van der Bruggen P, Hirsch T. Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation. Methods Cell Biol. 2025;191:151-196. doi: 10.1016/bs.mcb.2024.10.010. Epub 2024 Nov 25.
- Results publication: PubMed 29785656Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21.
- Results publication: PubMed 37931958Vanhaver C, Aboubakar Nana F, Delhez N, Luyckx M, Hirsch T, Bayard A, Houbion C, Dauguet N, Brochier A, van der Bruggen P, Bruger AM. Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. Life Sci Alliance. 2023 Nov 6;7(1):e202302332. doi: 10.26508/lsa.202302332. Print 2024 Jan.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer (Diagnosis)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frank Aboubakar Nana, MD; PhD study director
Cliniques universistaires saint Luc
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peripheral Blood Collection for Immune Profiling in people with Lung Cancer (Diagnosis) and Sarcoidosis, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Frank Aboubakar Nana, MD; PhD (0032 2 764 85 19, frank.aboubakar@saintluc.uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression free survival (time frame: Throughout the entire study, approximately during 7 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07384897, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.